New study sheds light on efficacy of ADHD meds

Learn how to distinguish true ADHD from anxiety, trauma, sleep issues, or substance use by tracing symptoms back to childhood across settings and impairment.

NHIS data show the share of US children aged 5 to 17 years ever diagnosed with ADHD climbed from 9.9% in 2019 to 13.8% in 2025.

Self-harm risk in ADHD peaked in the 90 days before medication initiation and declined once treatment began, a 5-system analysis found.

Lower maternal PlGF in the third trimester was tied to child ADHD in a University of Iowa cohort, independent of preeclampsia and FGR.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.

In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.

New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.